Featured news from NHIVNA
HIV-related news from NAM
Canada: PrEP use now could save considerable sums in the future
Gus Cairns, 2015-03-20 10:20:00
A Canadian paper that weighs the cost of using pre-exposure
prophylaxis (PrEP) to prevent HIV infections against the lifetime total cost of
one HIV infection finds that, using figures available for Quebec and Ontario
provinces, PrEP would be cost-saving under most scenarios, even if the overall lifetime
cost of HIV care falls in the future.
paper, published in January before the Conference on Retroviruses and Opportunistic Infections (CROI 2015), in fact almost
certainly underestimates the potential cost benefits of PrEP. The researchers
at the time of writing had access to estimates of the cost of PrEP and of HIV
care but did not have access to the actual effectiveness of PrEP as seen in
Ipergay, the study they use for their modelling. They therefore base their
estimation of the cost of one HIV infection averted on the efficacy seen in the
previous iPrEx study – 44%. In fact the effectiveness seen in Ipergay was 86% –
meaning that the cost per infection averted would be considerably less.
In addition, the researchers use a high estimate of the
overall cost of the drugs used in taking an Ipergay-style regimen. In the
event, the average cost per person was about half of this.